Tirzepatide vs AOD-9604.

Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once. It carries a C20 fatty diacid side chain that binds serum albumin, extending its half-life to roughly five days and enabling once-weekly subcutaneous dosing. It is the active ingredient in Eli Lilly's FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).

AOD-9604 ("Advanced Obesity Drug 9604") is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic region of human growth hormone (hGH), residues 177–191, with an added tyrosine at the N-terminus. It was engineered in the 1990s by researchers at Monash University and developed by the Australian biotech Metabolic Pharmaceuticals as an orally-investigated anti-obesity agent. The design goal was to isolate hGH's fat-mobilizing activity while leaving out the growth-promoting, IGF-1-stimulating actions of the full hormone.

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, the first approved agent to engage both incretin pathways. Through GLP-1 receptor activation it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation contributes additional insulinotropic effects and is thought to influence energy metabolism and adipose tissue handling. Its peptide backbone is more closely modeled on native GIP, and it is biased toward GIP-receptor engagement relative to GLP-1, though the precise contribution of the GIP arm to its clinical effect in humans remains an area of active investigation. The net clinical result is improved glycemic control and substantial reductions in body weight and food intake.

In rodent models, AOD-9604 reproduces the lipolytic (fat-breakdown) and fat-oxidation–promoting effects of full-length growth hormone without binding the GH receptor and without raising IGF-1. Mechanistic work in obese and beta-3-adrenergic-receptor knockout mice indicated its effect on fat metabolism is associated with modulation of beta-3 adrenergic receptor activity and increased lipolysis and fat oxidation rather than classic GH-receptor signaling. Because it does not engage the GH receptor, it was hypothesized to avoid the insulin-resistance and tissue-growth liabilities of GH itself. Importantly, the cleanly receptor-independent, IGF-1-sparing profile is best characterized in animal and in-vitro work, not firmly established in humans.

Human evidence for tirzepatide is unusually robust, anchored by the large randomized SURPASS (diabetes) and SURMOUNT (obesity) programs. In SURPASS-2 (Frias et al., NEJM 2021), tirzepatide produced greater HbA1c and body-weight reductions than injectable semaglutide in type 2 diabetes across all doses. In the placebo-controlled SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity or overweight lost roughly 15–21% of body weight on average depending on dose. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed reductions in apnea-hypopnea index in patients with obesity and moderate-to-severe obstructive sleep apnea, supporting the December 2024 FDA approval for that indication. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) and the SUMMIT heart-failure-with-preserved-ejection-fraction program have reported results, but long-term hard-outcome data are newer and still being integrated; readers should treat cardiovascular benefit as supported but more recently established than the glycemic and weight findings.

Preclinical evidence is the strongest part of the AOD-9604 record: chronic dosing reduced body-weight gain and increased fat oxidation in obese mice (Heffernan et al., Int J Obes, 2001; PMID 11673763). It progressed into human obesity trials in the early-mid 2000s; a 12-week randomized study reported only a modest separation from placebo (on the order of ~1–2 kg), and development was halted around 2007 after a larger ~24-week trial failed to show meaningful weight-loss efficacy, particularly once diet and exercise were standardized. No peer-reviewed pivotal trial demonstrates clinically useful weight loss, and there is no robust human evidence for the commonly marketed claims around cartilage, joint, or tendon repair: those rest on limited preclinical/early work. In short, the human data are negative-to-thin for obesity and largely absent for other indications.

The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, typically arising during dose escalation and often diminishing over time. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies (the human relevance is unknown), and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Documented risks include acute pancreatitis, gallbladder disease, acute kidney injury (often via dehydration from GI losses), hypersensitivity reactions, and hypoglycemia when combined with insulin or sulfonylureas. Important unknowns remain around long-term safety, effects of regained weight after discontinuation, use in pregnancy, and potential reduced effectiveness of oral medications (including oral contraceptives) due to delayed gastric emptying.

Across the obesity trials, AOD-9604 was generally reported as well tolerated with a clean short-term safety signal, which is part of why it was later nominated for compounding review; however, these data come from time-limited studies and do not establish long-term safety. There is no established safety profile for chronic use, for injectable research-grade ("gray market") product, or for the unindicated cosmetic, joint, and anti-aging uses now marketed online. Purity, identity, and contamination of non-pharmaceutical material are real concerns, underscored by published forensic identification of illicit AOD9604 preparations (Drug Testing and Analysis, 2014; PMID 24976118). No dosing or administration guidance is provided here.

Tirzepatide is FDA-approved (not investigational): as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); it is also authorized in the EU, UK, and other jurisdictions. It is a prescription drug, and compounded or research-grade "tirzepatide" sold outside the regulated supply chain is not FDA-approved and carries quality and safety risks.

AOD-9604 is not approved by the FDA (or any major regulator) for any therapeutic use; its obesity development program was discontinued, and it remains investigational/research-use-only. The FDA has evaluated it among nominated bulk drug substances for pharmacy compounding under section 503A and has flagged peptide candidates of this type as raising significant safety questions; it is also prohibited in sport and tested for by anti-doping authorities under the WADA framework.